

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 March 2001 (15.03.2001)

PCT

(10) International Publication Number  
**WO 01/17546 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 38/13**,  
9/50, 9/51

(21) International Application Number: PCT/US00/24505

(22) International Filing Date:  
7 September 2000 (07.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/392,557 9 September 1999 (09.09.1999) US

(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:  
US 09/392,557 (CIP)  
Filed on 9 September 1999 (09.09.1999)

(71) Applicant (for all designated States except US): **ELAN  
PHARMA INTERNATIONAL LTD.** [IE/IE]; Wil House,  
Shannon County Clare (IE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BOSCH, H.,**

**William** [US/US]; 237 Rodney Circle, Bryn Mawr, PA  
19010 (US). **OSTRANDER, Kevin, D.** [US/US]; 227  
Sunrise Road, Reading, PA 19606 (US). **HOVEY, Dou-  
glas, C.** [US/US]; 16 Hunt Club Drive, Collegeville, PA  
19426 (US).

(74) Agent: **BENT, Stephen, A.**; Foley & Lardner, 3000 K  
Street, NW, Suite 500, Washington, DC 20007-5109 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

[Continued on next page]

(54) Title: NANOPARTICULATE COMPOSITIONS COMPRISING AMORPHOUS CYCLOSPORINE AND METHODS OF MAKING AND USING SUCH COMPOSITIONS



(57) Abstract: Nanoparticulate amorphous cyclosporine formulations, and nanoparticulate cyclosporine formulations comprising a mixture of amorphous and crystalline cyclosporine, having effective average particle sizes of less than about 2000 nm are described. The compositions exhibit increased bioavailability and increased consistency of bioavailability as compared to prior macro-sized cyclosporine and formulations. Methods of making and using the compositions are also described.



WO 01/17546 A1